CompletedNot Applicable

Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation

France262 participantsStarted 2011-12

Plain-language summary

The aim of this registry is to provide information, in day-to-day practice, on Plerixafor prescription modalities in France, over a 13-month period in order to address the health authorities' request.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients treated with Plerixafor for autologous transplantation between November 2011 and November 2012 * Patients who have been informed and who have given their written consent for the access to their medical file Exclusion Criteria: * Patients already included in a Plerixafor ongoing clinical trial.

What they're measuring

The characteristics of the patients who received treatment

Timeframe: 13 months

Dosage of treatment

Timeframe: 13 months

Number of CD34+ cells collected following treatment

Timeframe: 13 months

Number of patients with the existence of one or more predictive factors of poor mobilisation

Timeframe: 13 months

Duration of treatment

Timeframe: 13 months

Associated treatments

Timeframe: 13 months

Trial details

NCT IDNCT01738373

SponsorGenzyme, a Sanofi Company

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2012-11

View on ClinicalTrials.gov More Bone Marrow / Autologous Transplants trials